What You Should Know
- AiZtech Labs has officially launched iSelfie BioSignals in the U.S., a smartphone-based platform that detects digital biomarkers using a standard selfie-camera interaction.
- The platform is designed to generate clinically meaningful measurements from the eye and surrounding skin, helping care teams prioritize patients faster and reduce reliance on device-heavy hardware.
- Clinical validation includes data from over 5,000 human participants across six studies in the U.S., Canada, and international markets, covering cardiovascular and respiratory use cases.
- International deployment data showed the technology reduced traditional intake workflows from 7 minutes to 2 minutes, generating an estimated $4.8 million in annual savings for one hospital cluster.
- The technology holds regulatory approval from the Saudi Food and Drug Authority (SFDA) for measuring heart rate, blood oxygen saturation (SpO2), and calibrated blood pressure.
The U.S. healthcare system is currently facing a “triple threat” of acute nursing shortages, the high cost of expanding traditional care models, and mounting delays in patient access. AiZtech Labs is moving to address these bottlenecks with the U.S. debut of iSelfie BioSignals. By transforming the ubiquitous smartphone into a sophisticated diagnostic tool, the company aims to upgrade the traditional “clinical signals layer”—the manual process of taking vitals that often clogs care delivery before treatment even begins.
Unlike traditional triage, which requires scarce human resources and expensive, bulky equipment, iSelfie BioSignals allows for early assessment through a low-friction “selfie” interaction. This Vision AI infrastructure is designed to help providers quickly determine who requires immediate intervention and who can be safely routed to lower-acuity care paths, effectively acting as a force multiplier for overstretched clinical teams.
Clinical Rigor and International Success
The U.S. launch is supported by a foundation of rigorous clinical work. The platform has been validated in controlled settings involving more than 5,000 participants. Notably, operational use by the Ministry of Health in Saudi Arabia—including deployment during the high-volume Hajj 2025 event—demonstrated the technology’s ability to perform in high-pressure, real-world environments.
In the Makkah Al-Mukarramah Health Cluster, the technology was benchmarked against medical-grade ground-truth measurements. The results were significant: the intake process was slashed by five minutes per patient, dramatically improving throughput and reducing the administrative burden on nursing staff. Mohamed Sheta, co-founder and CEO of AiZtech Labs, noted that this “Vision AI infrastructure layer” is intended to replace the human-machine bottlenecks that have gated access to clinical decision-making for decades.
Scaling Access Beyond the Physical Exam Room
Following a strong reception at HIMSS 2026, where more than 40 U.S. health systems expressed early interest, AiZtech Labs is focusing its initial U.S. efforts on partnerships with providers, population health organizations, and care-delivery leaders. The goal is to deploy iSelfie BioSignals in settings where organizations are seeking scalable alternatives to hardware-heavy workflows.
By moving clinical signals from specialized machines to the patient’s own device, iSelfie BioSignals offers a path toward earlier intervention and continuous monitoring that extends beyond the walls of the hospital. As health systems look for new ways to engage patients and manage risk at scale, this low-burden approach provides a critical tool for building a more responsive, data-driven front end for modern healthcare.
Why This Matters
AiZtech Labs is tackling the “First Mile” problem in healthcare. While the industry has spent billions on Electronic Health Records (EHRs), the actual process of getting data into the record remains analog, manual, and slow. iSelfie BioSignals is effectively attempting to “digitize” the physical exam itself.
